Association of GST polymorphism with adverse drug reactions: an analysis across multiple drug categories.

Expert opinion on drug metabolism & toxicology Pub Date : 2025-01-01 Epub Date: 2024-11-06 DOI:10.1080/17425255.2024.2426616

Soukaina Ettoury, Sara Louati, Ibtissam Saad, Kaoutar Bentayebi, Oumaima Zarrik, Jamal Eddine Bourkadi, Lahcen Belyamani, Youssef Daali, Rachid Eljaoudi

{"title":"Association of GST polymorphism with adverse drug reactions: an analysis across multiple drug categories.","authors":"Soukaina Ettoury, Sara Louati, Ibtissam Saad, Kaoutar Bentayebi, Oumaima Zarrik, Jamal Eddine Bourkadi, Lahcen Belyamani, Youssef Daali, Rachid Eljaoudi","doi":"10.1080/17425255.2024.2426616","DOIUrl":null,"url":null,"abstract":"Introduction: Adverse drug reactions (ADRs) pose a significant challenge in clinical practice, impacting patient safety and treatment outcomes. Genetic variations in drug-metabolizing enzymes, particularly glutathione S-transferases (GSTs), have been implicated in modulating individual susceptibility to ADRs.Areas covered: This overview aims to explore the association between GSTs genetic polymorphisms and ADRs across diverse drug categories documented in current literature. Here we cover antiepileptic, immunosuppressive, chemotherapeutic agents, analgesics, antivirals, and antibiotics.Expert opinion: According to the existing literature, the association between genetic polymorphisms in GST theta (GSTT1), GST mu (GSTM1), and GST pi (GSTP1) and adverse drug reaction occurrence has been frequently reported. However, the strength of these associations varies considerably among studies, with some showing inconsistent or contradictory results, underscoring the need for further investigations.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"191-201"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert opinion on drug metabolism & toxicology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17425255.2024.2426616","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/6 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Adverse drug reactions (ADRs) pose a significant challenge in clinical practice, impacting patient safety and treatment outcomes. Genetic variations in drug-metabolizing enzymes, particularly glutathione S-transferases (GSTs), have been implicated in modulating individual susceptibility to ADRs.

Areas covered: This overview aims to explore the association between GSTs genetic polymorphisms and ADRs across diverse drug categories documented in current literature. Here we cover antiepileptic, immunosuppressive, chemotherapeutic agents, analgesics, antivirals, and antibiotics.

Expert opinion: According to the existing literature, the association between genetic polymorphisms in GST theta (GSTT1), GST mu (GSTM1), and GST pi (GSTP1) and adverse drug reaction occurrence has been frequently reported. However, the strength of these associations varies considerably among studies, with some showing inconsistent or contradictory results, underscoring the need for further investigations.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

GST 多态性与药物不良反应的关系：对多种药物类别的分析。

简介药物不良反应（ADRs）是临床实践中的一项重大挑战，影响着患者的安全和治疗效果。药物代谢酶，尤其是谷胱甘肽 S-转移酶（GSTs）的基因变异与个体对 ADRs 的易感性有关：本综述旨在探讨现有文献中记载的不同药物类别中 GSTs 基因多态性与 ADRs 之间的关联。在此，我们涵盖了抗癫痫药、免疫抑制剂、化疗药、镇痛药、抗病毒药和抗生素：根据现有文献，GST theta（GSTT1）、GST mu（GSTM1）和 GST pi（GSTP1）的基因多态性与药物不良反应发生率之间的关联已被频繁报道。然而，这些关联的强度在不同的研究中差别很大，有些研究结果不一致或相互矛盾，这说明有必要进行进一步的调查。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert opinion on drug metabolism & toxicology

自引率

0.00%

发文量